Photo/Shetuwang

NBD AI Bulletin，China National Medicines Corporation Ltd. (the Company, SH 600511, closing price: 49.52 yuan) announced on the evening of June 24 that the cumulative intraday closing price deviation of the Company's shares over three consecutive trading days (June 22, June 23 and June 24) had exceeded 20%.

A self-examination shows that since the coronavirus outbreak, the Company's operations have been affected to a certain extent, but the internal operation is normal and the Company does not have any material information that should have been disclosed.

At the same time, the vaccine in media reports belongs to China National Biotec Group Company Limited (China National Biotec Group), which shares the actual controller with the Company but there is no equity relationship between each other. The Company does not distribute vaccines and does not have direct vaccine business with China National Biotec Group.

NBD AI Review: Shares of China National Medicines Corporation Ltd. rose 37.52% in the last five trading days, while the pharmaceutical and biological sector rose 0.8% and the Shanghai Composite Index gained 1.49% over the same period.

According to the 2019 annual report, China National Medicines Corporation Ltd. mainly engages in pharmaceutical commerce, pharmaceutical industry, warehousing logistics, and internal offsets, accounting for 103.4%, 2.23%, 0.54% and -6.38% of its revenue, respectively.

The chairman of China National Medicines Corporation Ltd. is Jiang Xiuchang, male, 56 years old, master's degree. The general manager of China National Medicines Corporation Ltd. is Li Hui, male, 51 years old, college degree, assistant accountant.

(By Tan Yuhan)

Disclaimer: This article is for informational purposes only and does Not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.